A review on cardio-hepatic toxic macrolide: Azithromycin
Keywords:
Azithromycin, Macrolide, QT interval, DILI, HepatotoxicityAbstract
Drug-induced cardio-hepatic toxicity is the foremost cause of heart and liver damage, with the use of antimicrobial-agent. Most patients, although recuperate after discontinuing the offending-agent, severe cases may consequence in progressive disease. Azithromycin is a rare cause of idiosyncratic drug-induced cardiac and liver injury. This semi-synthetic macrolide has a substantial potency against both gram-positive and gram-negative organisms due to the presence of a nitrogen atom in its ring. A search was performed in PubMed, Scopus, Google Scholar and Research Gate. Azithromycin divulges a lower number of interactions with proteins, whereas, QTc prolongation with torsades de pointes (Tdp) and polymorphic ventricular tachycardia are communally occurred in cardiovascular system, due to dysregulation of intracellular [Ca++] via the Na+-Ca++ exchanger activity, leading to delayed after depolarizations. In addition azithromycin-induced liver injury was more cholestatic in nature, with an ALT/ALP ratio of <2 ULN, contributing vanishing bile duct syndrome. This review hereafter revealed the adverse effect of azithromycin in relation with cardio – hepatic toxicity.
Downloads
References
Aspromonte, N., Monitillo, F., Puzzovivo, A., Valle, R., Caldarola, P., Iacoviello, M. (2014). Modulation of cardiac cytochrome P450 in patients with heart failure. Expert Opin Drug Metab Toxicol, 10 (3), 327-339
Bessone, F., Hernández, N., Tanno, M. E., Roma, M.G. (2021). Drug-Induced Vanishing Bile Duct Syndrome: From Pathogenesis to Diagnosis and Therapeutics. Semin Liver Dis, 41 (03), 331-348
Bloomingdale, P., Housand, C., Apgar, B J. F., Millard, jL., Mager, D. E., Burke, J. M., Shah, D. K.(2017). Quantitative systems toxicology. Curr Opin Toxicol, 4, 79-87
Cambell, K. B. (2022). Chapter 10 – Antimicrobial agents and torsades de pointes, Editor (s): James E. Tisdale, Torsades de Pointes, Academic Press, 231-266
Chalasani, N. P., Hayashi, P. H., Bonkovsky, H. L., Navarro, V. J., Lee, W. M., Fontana, R. J. (2014). ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol, 109, 950–966
Chalasani, N., Bonkovsky, H. L., Fontana, R., Lee, W., Stolz, A., Talwalkar, J., Reddy, K. R,., Watkins, P. B., Navarro, V., Barnhart, H., Gu, J., Serrano, J. (2015). United States Drug Induced Liver Injury Network. Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study. Gastroenter, 148 (7), 1340-52.e7
Chandrupatla, S., Demetris, A. J., Rabinovitz, M. (2002). Azithromycin-induced intrahepatic cholestasis. Dig Dis Sci, 47, 2186–2188
Chitturi, S., Farrell, G. C. (2001). Drug-induced cholestasis. Semin Gastrointest Dis, 12, 113-124
Chorin, E., Wadhwani, L., Magnani, S., Dai, M., Shulman, E., Nadeau-Routhier, C., Knotts, R., Bar-Cohen, R., Kogan, E., Barbhaiya, C., Aizer, A., Holmes, D., Bernstein, S., Spinelli, M., Park, D. S., Stefano, C., Chinitz, L. A., Jankelson, L. (2020). QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin. Heart Rhythm, 17 (9), 1425–1433.
Das, B. K. (2011). Azithromycin induced hepatocellular toxicity and hepatic encephalopathy in asymptomatic dilated cardiomyopathy. Indian J Pharmacol, 43 (6), 736–737
Dawkins, M., Fishkin, T., Gavriel Berman, G., Wang, A., Saidman, J., Partiula, B. (2023). Severe Azithromycin-Induced Liver Injury With Vanishing Bile Duct Syndrome Necessitating Liver Transplantation. . AIM Clinical Cases, 2, e230251
Derendorf, H. (2020). Excessive lysosomal ion-trapping of hydroxychloroquine and azithromycin. International Journal of Antimicrobial Agents, 55 (6), 106007
Devarbhavi, H. (2012). An update on drug-induced liver injury. J Clin Exp Hepatol, 2, 247-259
Dhar, R., Talwar, D., Singh, V., Dumra, H., Rajan, S., Jindal, S.K. (2021). Expert recommendations on the role of macrolides in chronic respiratory diseases. Lung India, 38 (2), 174-182
Drew, B. J., Ackerman, M.J., Funk, M., Gibler, W. B., Kligfield, P., Menon, V., Philippides, G. J., Roden, D. M., Zareba, W. (2010). Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Cir, 121 (8), 1047–1060
Drew, R. H., Gallis, H. A. (1992). Azithromycin--spectrum of activity, pharmacokinetics, and clinical applications. Pharmacotherapy, 12 (3), 61-73
Dzhura, I., Wu, Y., Colbran, R., Balser, J., Anderson, M. (2000). Calmodulin kinase determines calciumdependent facilitation of L-type calcium channels. Nature Cell Biol, 2,173–177
Elbekai, R. H., El-Kadi, A. O. S. (2006). Cytochrome P450 enzymes: central players in cardiovascular health and disease. Pharmacol Ther, 112 (2), 564-587
Farag, N. E., El-Kherbetawy, M. K., Ismail, H. M., Abdelrady, A. M., Toraih, E. A., Abdelbasset, W. K., Lashine, R. M., EL-dosoky, M., Abed, S. Y., Ibraheem, K. M., Fawzy, M. S., Zaitone, S. A. (2021). Differential Effect of Three Macrolide Antibiotics on Cardiac Pathology and Electrophysiology in a Myocardial Infarction Rat Model: Influence on Sodium Nav1.5 Channel Expression. Pharmaceuticals, 14, 597
Fisher, K., Vuppalanchi, R., Saxena, R. (2015). Drug-Induced Liver Injury. Arch Pathol Lab Med, 139 (7), 876-887
Fohnera, A. E., Sparreboomb, A., Altmana, R. B., Klein, T. E. (2017). PharmGKB summary: macrolide antibiotic pathway, pharmacokinetics/pharmacodynamics. Pharmacogenet Genomics, 27 (4), 164–167
Francis, P., Navarro, V. J. (2022). Drug-Induced Hepatotoxicity. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing
Giudicessa, J. R., Ackerman, M. J. (2012). Azithromycin and risk of sudden cardiac death: Guilty as charged or falsely accused? Cleveland Clinic Journal of Medicine, 8 (9), 539-544
Han, B., Sheng, Y., Wang, L., Feng, H., Hou, X., Li, Y. (2017). Intrahepatic cholestasis of pregnancy or azithromycin-induced intrahepatic cholestasis. Med (Baltimore), 96 (52), e9346
Han, Y., Zhang, J., Hu, C. Q., Zhang, X., Ma, B., Zhang, P. (2019). In Silico ADME and Toxicity Prediction of Ceftazidime and its Impurities. Front Pharmacol, 10, 434. 10.3389/fphar.2019.00434
He, X. J., Zhao, L. M., Qiu, F., Sun, Y. X., Li-Ling, J. (2009). Influence of ABCB1 gene polymorphisms on the pharmacokinetics of azithromycin among healthy Chinese Han ethnic subjects. Pharmacol Rep, 61, 843-850
Howell, B. A., Yang, Y., Kumar, R., Woodhead, J. L., Harrill, A. H., Clewell, H. L., Andersen, M. E., Siler, S. Q., Watkins, P. B. (2012). In vitro to in vivo extrapolation and species response comparisons for drug‐induced liver injury (DILI) using DILIsymTM: a mechanistic, mathematical model of DILI. J Pharmacokinet Pharmacodyn, 39, 527‐541
Huang, B., Wu, C., Hsia, C., Yin Chen, C. (2007). Azithromycin-induced torsade de pointes. Pacing Clin Electrophysiol, 30, 1579–1582
Idkaidek, N. M., Naji Najib, N., Salem, I., Jilani, J. (2014). Physiologically-Based IVIVC of Azithromycin. Am J Pharmacol Sc,i 2 (6), 100-102
Ioannidis, J. P., Contopoulos-Ioannidis, D. G., Chew, P., Lau, J. (2001). Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for upper respiratory tract infections. J Antimicrob Chemother, 48 (5), 677-689
Kallip, T., Payne, M. A. (1960). High Serum Transaminase Activity in Heart Disease: Circulatory Failure and Hepatic Necrosis. Cir, 21 (5), 646 – 660
Katarey, D., Verma, S. (2016). Drug-induced liver injury. Clin Med (Lond), 16 (6), s104-s109
Kezerashvili, A., Khattak, H., Barsky, A., Nazari, R. (2007). Azithromycin as a cause of QT-interval prolongation and torsade de pointes in the absence of other known precipitating factors. J Interven Car Electrophysiol, 18 (3), 243-246
Kryfti, M., Bartziokas, K., Papaioannou, A. I., Papadopoulos, A., Kostikas, K. (2013). Clinical effectiveness of macrolides in diseases of the airways: Beyond the antimicrobial effects. Pneumon, 26, 33-46
Kutlin, A., Roblin, P. M., Hammerschlag, M. R. (2002). Effect of prolonged treatment with azithromycin, clarithromycin, or levofloxacin on Chlamydia pneumoniae in acontinuous-infection model. Antimicrob Agents Chemother, 46, 409–412
Lalak, N. J., Morris, D.L. (1993). Azithromycin clinical pharmacokinetics. Clin Pharmacokinet, 25, 370-374
Lenz, K. D., Klosterman, K. E., Mukundan, H., Kubicek-Sutherland, J. Z. (2021). Macrolides: From Toxins to Therapeutics. Toxins, 13, 347
Lewis, J. H. (2013). Drug-Induced Liver Injury Throughout the Drug Development Life Cycle: Where We Have Been, Where We are Now, and Where We are Headed. Perspectives of a Clinical Hepatologist. Pharm Med, 27, 165–191
Li, M., Ramos, L. G. (2017). Drug-Induced QT Prolongation And Torsades de Pointes. P T, 42 (7), 473–477
Liang, R., Ramdass, A. (2022). Azithromycin-Induced Liver Injury in an Asthma Exacerbation Patient With Autoimmune Features. Cureus, 14 (5), e25447
LiverTox. (2012). Clinical and Research Information on DrugInduced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases, Macrolide Antibiotics. https://www.ncbi.nlm.nih.gov/books/NBK547852/
Lockwood, A. M., Cole, S., Rabinovich, M. (2010). Azithromycin-induced liver injury. Am J Health Syst Pharm, 67, 810-814
Martinez, M. A., Vuppalanchi, R., Fontana, R. J., Stolz, A., Kleiner, D. E., Hayashi, P. H., Gu, J., Hoofnagle, J. H., Chalasani N. (2015). Clinical and Histologic Features of Azithromycin-Induced Liver Injury. Clinical Gastroenterology and Hepatology, 13, 369–376
Mitchell, G. F., Jeron, A., Koren, G. (1998). Measurement of heart rate and Q-T interval in the conscious mouse. Am J Physiol, 274, H747–H751
Moy, B. T., Dojki, F. K., Scholes, J. V., Hoffman, M. G. (2015). Azithromycin-induced cholestatic hepatitis. Conn Med, 79, 213–215
Ong, C. E., Pan, Y., Mak, J. W. (2017). The roles of cytochromes P450 in vascular biology and cardiovascular homeostasis. Int J Clin Exp Med, 10 (1), 1624-1636
Park, H. J., Seo, K. II., Yong, C. II. (2020). Liver transplantation for azithromycin-induced severe liver injury. Korean J Transplant, 34 (4), DOI:10.4285/kjt.20.0017
Parnham, M. J., Haber, V. E., Giamarellos-Bourboulis, E. J., Perletti, G., Verleden, G. M., Vos, R. (2014). Azithromycin: mechanisms of action and their relevance for clinical applications. Pharmacol Ther, 143(2), 225-245
Rao, G. A., Mann, J. R., Shoaibi, A., Bennett, C. L., Nahhas, G., Sutton, S. S., Jacob, S., Strayer, S. M. (2014). Azithromycin and levofloxacin use and increased risk of cardiac arrhythmia and death. Ann Fam Med, 12, 121–127
Ray, W. A., Murray, K. T., Hall, K., Arbogast, P. G., Stein, C. M. (2012). Azithromycin and the Risk of Cardiovascular Death. N Engl J Med, 366 (20), 1881-1890
Sandman, Z., Iqbal, O. A. (2024). Azithromycin. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing
Sharma, K., Mullangi, R.(2013). A concise review of HPLC, LC-MS and LC-MS/MS methods for determination of azithromycin in various biological matrices. Biomed Chromatogr, 27 (10), 1243-1258
Shoda, L., Woodhead, J. L., Siler, S. Q, Watkins, P. B., Howell, B. A. (2014). Linking physiology to toxicity using DILIsym®, a mechanistic mathematical model of drug‐induced liver injury. Biopharm Drug Dispos, 35, 33‐49
Sugie, M., Asakura, E., Zhao,Y. L., Torita, S., Nadai, M., Baba, K., Kitaichi, K., Takagi, K., Takagi, K., Hasegawa, T. (2004). Possible Involvement of the Drug Transporters P Glycoprotein and Multidrug Resistance-Associated Protein Mrp2 in Disposition of Azithromycin. Antimicrobial Agents and Chemotherapy, 48 (3), 809–814
Suresh, B. K., Kastelik, J., Morjaria, J. B. (2013). Role of long term antibiotics in chronic respiratory diseases. Respir Med, 107, 800‑815
Swayze, E. E., Griffey, R. H., Bennett, C. F. (2007). 2.26 -Nucleic Acids (Deoxyribonucleic Acid and Ribonucleic Acid). Comprehensive Medicinal Chemistry II, 2, 1037-1052
Tsai, D., Jamal, J. A., Davis, J., Lipman, J., Roberts, J. (2015). Interethnic differences in pharmacokinetics of antibacterials. Clin Pharmacokinet, 54 (3), 243-260
Vial, T., Biour, M., Descotes, J., Trepo, C. (1997). Antibiotic-associated hepatitis: update from 1990. Ann Pharmacother, 31, 204-220
Viluksela, M., Vainio, P. J., Tuominen, R. K. (1996). Cytotoxicity of macrolide antibiotics in a cultured human liver cell line. J Antimicrob Chemother, 38, 465-473
Wong, K. M., Hosseinnejad, K., Palaparty, P., Ravakhah, K. (2021). Azithromycin-Induced Liver Injury in Legionnaires' Disease. Cureus, 13 (9), e17856
Woodhead, J. L., Brock, W. J., Roth, S. E., Shoaf, S. E., Brouwer, K. L. R., Church, R., Grammatopoulos, T. N., Stiles, L., Siler, S. Q., Howell, B. A., Mosedale, M., Watkins, P. B., Shoda, L. K. M. (2017). Application of a mechanistic model to evaluate putative mechanisms of tolvaptan drug‐induced liver injury and identify patient susceptibility factors. Toxicol Sci Off J Soc Toxicol, 155, 61‐74
Woodhead, J. L., Yang, K., Oldach, D., MacLauchlin, C., Fernandes, P., Watkins, P. B., Siler, S. Q., Howell, B. A. (2019). Analyzing the mechanisms behind macrolide antibiotic‐induced liver injury using quantitative systems toxicology modeling. Pharm Res, 36, 48
Wu, Y., Bi, W. T., Qu, L. P., Fan, J., Kong, X. J., J, C. C., Chen, X. M., Yao, F. J., Liu, L. J., Cheng, Y. J., Wu, S. H. (2023). Administration of macrolide antibiotics increases cardiovascular risk. Front Cardiovasc Med, 10, 1117254. doi: 10.3389/fcvm.2023.1117254
Yang, Y., Nadanaciva, S., Will, Y., Woodhead, J. L., Howell, B. A., Watkins, P. B., Siler, S. Q. (2015). MITOsym®: A Mechanistic, Mathematical Model of Hepatocellular Respiration and Bioenergetics. Pharm Res, 32, 1975–1992
Yang, Z., Prinsen, J. K., Bersell, K. R., Shen, W., Yermalitskaya, L., Sidorova, T., Luis, P. B., Hall, L., Zhang, W., Du, L., Milne, G., Tucker, P., George Jr, A. L., Campbell, C. M., Pickett, R. A., Shaffer, C. M., Chopra, N., Yang, T., Knollmann, C. B., Roden, D. M., Murray, K. T. (2017). Azithromycin Causes a Novel Proarrhythmic Syndrome. Circ Arrhythm Electrophysiol, 10 (4), doi:10.1161/CIRCEP.115.003560
Yap, Y.G., Camm, A. J. (2003). Drug-induced QT prolongation and torsades de pointes. Heart, 89 (11), 1363–1372
Zhang, H., Zou, J., Yan, X., Chen, J., Cao, X., Wu, J., Liu, Y., Wang, T. (2021). Marine-Derived Macrolides 1990–2020: An Overview of Chemical and Biological Diversity. Mar. Drugs, 19, 180
Zhang, M. Q., Zhang, J. P., Hu, C. Q. (2022). A Rapid Assessment Model for Liver Toxicity of Macrolides and an Integrative Evaluation for Azithromycin Impurities. Front Pharmacol, 13, 860702
Zuckerman, J. M. (2004). Macrolides and ketolides: azithromycin, clarithromycin, telithromycin. Infect Dis Clin North Am, 18 (3), 621–649
Zuckerman, J. M., Qamar, F., Bono, B. R. (2011). Review of macrolides (azithromycin, clarithromycin), ketolids (telithromycin) and glycylcyclines (tigecycline). Med Clin North Am, 95 (4), 761-791
Published
How to Cite
Issue
Section
Copyright (c) 2024 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
